Itolizumab (DB16207): A Comprehensive Monograph on a First-in-Class Anti-CD6 Immunomodulator

Executive Summary

[Itolizumab is a first-in-class, humanized IgG1 kappa monoclonal antibody that represents a novel approach to immunomodulation by selectively targeting the CD6 co-stimulatory receptor on T-cells. Developed jointly by the Center of Molecular Immunology in Cuba and Biocon in India, the drug has a bifurcated history of regional commercial success and significant developmental challenges in Western markets. It is approved and marketed in India under the brand name ALZUMAb™ for the treatment of moderate-to-severe chronic plaque psoriasis and, under a restricted emergency use authorization, for cytokine release syndrome (CRS) in patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) due to COVID-19.]

[The core of Itolizumab's therapeutic potential lies in its unique mechanism of action. It binds to the SRCR1 domain of CD6, modulating the interaction with its ligand, ALCAM, without directly blocking it. This results in the selective downregulation of pathogenic T effector cell (Teff) activity and proliferation, particularly of the Th1 and Th17 lineages, while preserving the function of crucial T regulatory cells (Tregs). This upstream intervention leads to a broad suppression of pro-inflammatory cytokines, including TNF-α, IFN-γ, IL-6, and IL-17. This selective mechanism is the biological foundation for the drug's most compelling clinical attribute: a consistently favorable safety profile characterized by a notably low risk of serious infections, a key differentiator from many existing biologics and immunosuppressants.]

[Clinically, Itolizumab's journey has been one of mixed outcomes. While it demonstrated efficacy in its pivotal psoriasis trial, its performance is generally considered less potent than that of leading IL-17 or IL-23 inhibitors, positioning it as a niche option where safety is paramount. Its repurposing for COVID-19-associated CRS was a major success, providing powerful real-world validation of its ability to quell systemic hyperinflammation. However, its most advanced program in Western markets—a Phase 3 trial (EQUATOR) for first-line acute graft-versus-host disease (aGVHD)—delivered a complex and ultimately disappointing result from a regulatory standpoint. The trial failed to meet its primary endpoint of improved response at Day 29, leading the U.S. Food and Drug Administration (FDA) to decline an accelerated approval pathway. This failure occurred despite the trial achieving multiple statistically significant and clinically meaningful long-term secondary endpoints, including improved durable complete response and failure-free survival, suggesting a disconnect between the drug's immunomodulatory timeline and conventional regulatory endpoints for acute inflammatory conditions.]

[In contrast, mid-stage clinical data in other chronic autoimmune diseases have been highly encouraging. A Phase 2 study in ulcerative colitis (UC) showed efficacy comparable to the standard-of-care adalimumab, and a Phase 1b study in lupus nephritis (LN) demonstrated rapid and deep reductions in proteinuria. These positive signals, combined with its strong safety record, suggest that the future of Itolizumab lies not in acute hyperinflammatory states but in the chronic management of autoimmune diseases where long-term safety, tolerability, and durable disease control are the most critical attributes. The strategic focus for its development has now pivoted towards these indications, where it has the potential to become a valuable, differentiated therapeutic option.]

Molecular Profile and Mechanism of Action

[Itolizumab is a complex biologic agent whose therapeutic activity is defined by its unique structure and its novel interaction with a key checkpoint in the adaptive immune system. Its mechanism of action distinguishes it from other immunomodulatory biologics, offering a more nuanced approach to controlling T-cell-mediated inflammation.]

Structure and Physicochemical Properties

Itolizumab is a humanized recombinant monoclonal antibody of the immunoglobulin G1 (IgG1) kappa isotype.[1] It is a large glycoprotein with a molecular weight reported in the range of 145.5 kDa to 148 kDa, composed of two identical heavy chains and two identical light chains interconnected by disulfide bonds.[1] As a biotech therapeutic, it is classified as an immunomodulatory and anti-inflammatory agent, specifically acting as a CD6 antigen inhibitor.[1]

The antibody is derived from a parent murine monoclonal antibody, ior T1, which was originally raised against T-cells from a patient with Sézary's syndrome and showed early therapeutic promise in autoimmune conditions like psoriasis and rheumatoid arthritis.[4] The humanization process, which involves grafting the murine complementarity-determining regions (CDRs) onto a human IgG1 framework, was undertaken to reduce the immunogenicity associated with murine antibodies while preserving the specific antigen-binding properties and therapeutic effects of the parent molecule.[4] The drug is known by several synonyms, including Alzumab-L, T1h, and Anti-CD6 monoclonal antibody h-T1.[3]

Characteristic	Description	Source(s)
Generic Name	Itolizumab	5
Brand Name (India)	ALZUMAb™	10
DrugBank ID	DB16207	1
CAS Number	1116433-11-4	1
Type/Class	Biotech, Humanized Monoclonal Antibody, Immunomodulator, Anti-CD6 Antigen Inhibitor	1
Isotype	Human IgG1 kappa	1
Molecular Weight	Approx. 146-148 kDa	1
Target	CD6 (SRCR Domain 1)	1
Originator	Center of Molecular Immunology (CIM), Havana	5
Developers	Biocon; Equillium	6
Table 1: Itolizumab - Key Drug Characteristics

The CD6-ALCAM Pathway: A Novel Immunomodulatory Target

The primary molecular target of Itolizumab is the Cluster of Differentiation 6 (CD6) antigen, a 105–130 kDa type I transmembrane glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) superfamily.[1] CD6 is predominantly expressed on the surface of mature T-lymphocytes and thymocytes, with some expression on B-cell subsets, making it a pan T-cell marker.[5] It functions as a critical co-stimulatory receptor that modulates T-cell activation, proliferation, differentiation, and trafficking to sites of inflammation.[12]

The natural ligand for CD6 is the Activated Leukocyte Cell Adhesion Molecule (ALCAM), also known as CD166.[11] ALCAM is expressed on various cells, including antigen-presenting cells (APCs), endothelial cells, and epithelial cells.[12] The interaction between CD6 on a T-cell and ALCAM on an APC is a key component of the immunological synapse, the specialized interface where T-cell activation occurs. This binding provides a crucial second signal, complementing the primary signal from the T-cell receptor (TCR), which is necessary for optimal T-cell activation and the subsequent differentiation into effector lineages.[11]

The extracellular portion of the CD6 protein is composed of three distinct SRCR domains. The binding site for the ALCAM ligand is located on the third, membrane-proximal domain (SRCR3).[11] Itolizumab, however, binds with high specificity to the most membrane-distal domain, SRCR1.[1][ This spatial separation of the antibody and ligand binding sites is fundamental to Itolizumab's unique mechanism of action.]

Selective T-Cell Modulation: The Core Mechanism

Unlike many therapeutic antibodies that function as direct antagonists by sterically hindering ligand-receptor interactions, Itolizumab employs a more nuanced immunomodulatory mechanism. In vitro studies have demonstrated that Itolizumab does not inhibit the binding of ALCAM to CD6.[7] Its binding to the distinct SRCR1 domain allows the natural CD6-ALCAM interaction at SRCR3 to occur. However, the presence of Itolizumab bound to SRCR1 is believed to render this interaction "nonproductive," effectively uncoupling the physical binding event from the downstream intracellular signaling required for full T-cell activation.[11] The precise biophysical basis for this effect may involve inducing a conformational change in the CD6 receptor, stimulating its internalization and downregulation from the cell surface, or inhibiting the formation of new functional receptor complexes.[11]

This non-competitive modulation results in a highly selective effect on T-cell populations. It preferentially downregulates the activity of pathogenic T effector cells (Teff), particularly the pro-inflammatory T helper 1 (Th1) and T helper 17 (Th17) cells, which are central drivers of tissue damage in numerous autoimmune diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease.[11] A critical aspect of this selectivity is the preservation of T regulatory cells (Tregs).[14][ Tregs are essential for maintaining immune homeostasis and self-tolerance; their preservation allows for ongoing immune surveillance and helps prevent the broad immunosuppression that can lead to opportunistic infections. This ability to dampen pathogenic responses while sparing regulatory functions is a key biological feature that likely underpins Itolizumab's favorable safety profile.]

Downstream Cytokine Suppression

By intervening at the upstream checkpoint of T-cell co-stimulation, Itolizumab prevents the full activation and proliferation of Teff cells. A direct consequence of this is a marked reduction in the synthesis and secretion of a wide array of pro-inflammatory cytokines that are the downstream effectors of T-cell-mediated inflammation.[1]

[Specifically, treatment with Itolizumab has been shown to decrease the production of key cytokines associated with the Th1 and Th17 pathways. These include:]

• Interferon-gamma (IFN-γ): A signature Th1 cytokine that activates macrophages and promotes inflammation.[1]
• Tumor Necrosis Factor-alpha (TNF-α): A pleiotropic cytokine central to systemic inflammation and a validated target in many autoimmune diseases.[1]
• Interleukin-6 (IL-6): A key driver of the acute phase response and a major contributor to cytokine release syndrome.[1]
• Interleukin-17 (IL-17): A hallmark cytokine of the Th17 lineage, crucial in the pathogenesis of psoriasis and other autoimmune conditions.[14]

This mechanism of acting "upstream" to broadly suppress multiple cytokine pathways is a fundamental point of differentiation from therapies that act "downstream" by targeting a single cytokine or its receptor, such as the anti-IL-6 receptor antibody Tocilizumab or the anti-IL-1 receptor antagonist Anakinra.[15] This broader effect on the inflammatory cascade provides a strong rationale for its efficacy in conditions characterized by widespread cytokine dysregulation, such as the cytokine storm seen in severe COVID-19. Furthermore, by modulating the T-cell response at its source rather than merely neutralizing its products, the therapeutic effect may be more durable, a possibility supported by clinical observations of sustained remission in psoriasis patients after treatment cessation.[12]

Biopharmaceutical Profile: Manufacturing and Formulation

[The production of Itolizumab, like other monoclonal antibodies, involves a complex and highly controlled biopharmaceutical manufacturing process, divided into upstream development (cell culture) and downstream processing (purification and formulation).]

Upstream Processing: Cell Line and Culture

Itolizumab is manufactured using recombinant DNA (r-DNA) technology, a standard for modern therapeutic antibodies.[18] The protein is expressed in a stable, well-characterized Chinese Hamster Ovary (CHO) cell line.[2][ CHO cells are the predominant mammalian host system for producing complex therapeutic glycoproteins because of their capacity for human-like post-translational modifications, such as glycosylation, which are critical for the antibody's stability, safety, and function.]

The CHO cells are grown in large-scale bioreactors under tightly controlled conditions. The culture process utilizes a chemically defined, animal-component-free medium, identified as BMH2R.[18][ The use of such a medium is a critical manufacturing feature that enhances process consistency and reduces the risk of introducing adventitious agents, such as viruses or prions, that could be associated with animal-derived components.]

Downstream Processing: Purification and Final Product

[Once the cell culture phase is complete and the antibody has been secreted into the culture medium, the downstream process begins with harvesting and clarification to separate the antibody from the cells and cellular debris. The subsequent purification cascade is designed to isolate Itolizumab to a very high degree of purity while removing host cell proteins, DNA, and other process-related impurities.]

The purification process for Itolizumab employs a multi-step chromatographic strategy that includes affinity chromatography and ion exchange chromatography.[18] Affinity chromatography, likely using a Protein A resin which binds specifically to the Fc region of IgG antibodies, serves as a powerful initial capture step that can achieve over 95% purity in a single step. This is followed by polishing steps, such as ion exchange chromatography, to remove remaining trace impurities. This robust process yields a final product with a purity of ≥99.0%.[1]

A crucial element of the downstream process for any biologic produced in a mammalian cell line is viral safety. The Itolizumab manufacturing process incorporates specific, validated steps for viral inactivation and removal to ensure the safety of the final product.[18] After purification, the final bulk drug substance is subjected to aseptic filtration, filled into vials, and lyophilized (freeze-dried) to produce a stable, solid powder for injection.[18]

Formulation, Presentation, and Administration

The final drug product, marketed as ALZUMAb-L™ in India, is presented as a sterile, white to pale yellow lyophilized powder in single-use vials, with each vial typically containing 100 mg of Itolizumab.[18] The formulation contains several excipients to ensure the stability and solubility of the antibody upon reconstitution, including Histidine (a buffer), Sucrose (a cryoprotectant/lyoprotectant), and Polysorbate 80 (a surfactant to prevent aggregation).[18]

For clinical use, Itolizumab is intended for intravenous (IV) infusion only. The lyophilized powder must first be reconstituted with sterile Water for Injection. The resulting solution is then further diluted into a 250 mL infusion bag of 0.9% Sodium Chloride (normal saline).[11] It is explicitly noted that the drug should not be diluted in dextrose solutions.[20]

Administration must be performed as a controlled IV infusion over a period of several hours; it should not be administered as a rapid IV push or bolus.[18] The infusion should be initiated at a slow rate (e.g., 25-50 mL/h) and can be increased if well tolerated.[18] The use of an in-line, sterile, non-pyrogenic, low protein-binding filter with a pore size of 1.2 µm or less is required during administration to remove any potential particulates.[18] To mitigate the risk of infusion-related reactions, pre-medication with an intravenous corticosteroid (e.g., 100 mg hydrocortisone or equivalent) and an antihistamine (e.g., pheniramine) is recommended approximately 30 minutes prior to the start of the infusion.[18]

Clinical Development and Efficacy Analysis

[Itolizumab has been investigated across a broad spectrum of T-cell-mediated inflammatory and autoimmune diseases. Its clinical development has yielded approvals in specific regions for certain indications while facing significant hurdles in others, creating a complex global narrative of its therapeutic value.]

Plaque Psoriasis: The Foundational Indication

Itolizumab's first major clinical success was in the treatment of moderate-to-severe chronic plaque psoriasis. It received marketing authorization for this indication from the Drugs Controller General of India (DCGI) in January 2013 and is also approved in Cuba.[5] In India, it is marketed under the trade name ALZUMAb™.[10]

The approval was based on the results of a pivotal Phase III, multicenter, double-blind, placebo-controlled clinical trial known as treat-Plaq.[5] This study successfully met its pre-specified primary endpoint, demonstrating a statistically significant improvement in the Psoriasis Area and Severity Index (PASI) 75 response rate (defined as at least a 75% reduction in the PASI score from baseline) at 12 weeks of treatment compared to placebo.[5] The typical dosing regimen for psoriasis involves an intravenous infusion of 1.6 mg/kg every two weeks for 12 weeks, followed by maintenance dosing every four weeks.[11]

While pivotal trial data established its efficacy, the competitive landscape for psoriasis is dominated by highly effective biologic agents, including TNF-α inhibitors (e.g., adalimumab), IL-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., guselkumab, risankizumab), many of which can achieve superior PASI 90 and PASI 100 response rates.[22] Published data and expert opinion suggest that while Itolizumab is effective, its efficacy may be comparatively modest when compared to these other biologics.[4] However, its value proposition in this crowded market is built upon a different foundation. Its unique safety profile, particularly the lower risk of infection, and its potential for durable, long-term remission—as evidenced by a case report of a patient remaining in remission for over five years after discontinuing therapy—position it as a valuable alternative.[12] It may be particularly well-suited for patients with contraindications to other biologics, those at high risk for infections, or as a long-term maintenance therapy where a less aggressive immunomodulatory approach is preferred. In markets like India, its more affordable cost compared to other biologics is also a significant competitive advantage.[25]

Acute Graft-Versus-Host Disease (aGVHD): A Complex Clinical Narrative

The most ambitious and advanced clinical program for Itolizumab in Western markets was for the first-line treatment of patients with moderate-to-severe aGVHD, a life-threatening complication of allogeneic stem cell transplantation. The Phase 3 EQUATOR study (NCT05263999) was a randomized, double-blind, placebo-controlled trial that evaluated Itolizumab added to standard-of-care corticosteroids.[27]

The trial's results presented a challenging paradox. It failed to meet its primary endpoint, which was the complete response (CR) rate at Day 29. There was no meaningful difference in either CR or overall response rate (ORR) between the Itolizumab and placebo arms at this early time point.[27][ This failure was the central reason cited by the U.S. FDA for its decision to deny an accelerated approval pathway.]

However, the study demonstrated statistically significant and clinically meaningful benefits in several critical, pre-specified long-term secondary endpoints [27][:]

• Complete Response at Day 99:[ The CR rate was significantly higher in the Itolizumab arm (44.9%) compared to the placebo arm (28.6%), with a p-value of 0.035.]
• Duration of Complete Response:[ The median duration of CR was dramatically longer for patients receiving Itolizumab (336 days) versus placebo (72 days), with a p-value of 0.017.]
• Failure-Free Survival:[ The median time to treatment failure (defined by death, need for new systemic therapy, or relapse) was more than doubled in the Itolizumab arm (154 days) compared to placebo (70 days), with a p-value of 0.043.]
• Overall Survival:[ A positive trend toward improved survival was observed, with a lower mortality rate in the Itolizumab group (24.4%) compared to the placebo group (32.5%).]

[This temporal disconnect between the early and late endpoints highlights a potential mismatch between Itolizumab's biological mechanism and the established regulatory framework for aGVHD. The Day 28/29 endpoint was established based on the rapid, potent immunosuppressive effects of corticosteroids. Itolizumab, however, functions not as a fast-acting suppressant but as a gradual immunomodulator that rebalances the immune system. It is therefore biologically plausible that its primary clinical benefits—such as converting initial partial responses into deep, durable complete responses and improving long-term, failure-free survival—would only manifest after this conventional primary endpoint window has passed. The FDA's strict adherence to the Day 29 outcome underscores the significant challenge for sponsors of novel immunomodulators, demonstrating that trial design and endpoint selection must be carefully aligned with the drug's mechanism, often requiring extensive negotiation with regulatory agencies to validate novel endpoints that can capture the true clinical benefit.]

Ulcerative Colitis (UC): Promising Proof-of-Concept

Itolizumab has shown significant promise in the treatment of ulcerative colitis, a form of inflammatory bowel disease. A Phase 2 randomized, double-blind study was conducted in biologic-naïve patients with moderate-to-severe UC, notable for its inclusion of both a placebo arm and an active-control arm using adalimumab, a globally recognized standard-of-care TNF-α inhibitor.[31]

At the 12-week primary endpoint analysis, Itolizumab demonstrated strong evidence of efficacy [31][:]

• Clinical Remission:[ The Itolizumab arm achieved a clinical remission rate of 23.3%, which was numerically superior to both the adalimumab arm (20.0%) and the placebo arm (10.0%).]
• Endoscopic Remission:[ The rate of endoscopic remission was 16.7% in the Itolizumab arm, identical to that of adalimumab and substantially better than placebo (6.7%).]

Achieving efficacy comparable to a potent, established therapy like adalimumab in a head-to-head component of a Phase 2 trial is a significant validation of the CD6-ALCAM pathway as a therapeutic target in UC. The results are further strengthened by the observation that the Itolizumab arm had a higher proportion of patients with severe disease at baseline, suggesting its efficacy may be even more robust in a balanced population.[31][ These positive data provide a clear and compelling rationale for advancing Itolizumab into Phase 3 development for this indication.]

Lupus Nephritis (LN): Targeting High Unmet Need

Itolizumab is also being developed for lupus nephritis, a severe kidney manifestation of systemic lupus erythematosus (SLE). The Phase 1b EQUALISE study (NCT04128579) was an open-label trial designed to evaluate the safety, tolerability, and clinical activity of subcutaneously administered Itolizumab in patients with active proliferative LN.[35]

The study yielded positive signals of clinical activity, demonstrating rapid and deep reductions in proteinuria, as measured by the urine protein-to-creatinine ratio (UPCR), a critical biomarker of kidney function and disease activity in LN.[38]

• An interim analysis of highly proteinuric subjects showed that 83% (5 of 6) achieved a complete or partial clinical response by week 28.[38]
• Final topline data from 16 patients showed that by week 36, the overall response rate (complete plus partial response) was 81.3% (13 of 16), with results comparable to those seen in pivotal trials of recently approved LN therapies.[39]
• Over 80% of subjects achieved a greater than 50% reduction in UPCR.[39]

In recognition of the significant unmet medical need for safer and more effective treatments for LN, the U.S. FDA granted Itolizumab Fast Track designation for this indication, a move designed to facilitate and expedite its development and review.[41]

Repurposing for COVID-19-Associated Cytokine Release Syndrome (CRS)

The COVID-19 pandemic provided a unique opportunity to test Itolizumab's mechanism in a setting of acute, life-threatening hyperinflammation. The rationale was that the severe "cytokine storm" driving ARDS in COVID-19 patients involved many of the same cytokines (IL-6, TNF-α) that Itolizumab is known to suppress.[16]

Based on this hypothesis, Itolizumab was granted 'restricted emergency use' authorization by the DCGI in India in July 2020 for the treatment of CRS in patients with moderate-to-severe ARDS due to COVID-19.[5] This approval was based on a small but impactful randomized controlled trial (n=30) conducted in India. The trial demonstrated a statistically significant reduction in one-month mortality: there were zero deaths among the 20 patients treated with Itolizumab, compared to three deaths among the 10 patients in the control arm who received only the best supportive care.[43] The treatment was also associated with significant suppression of inflammatory biomarkers.[43]

A subsequent, larger (n=300), single-arm, multicenter Phase IV study (RESURRECT) was conducted to further evaluate safety and efficacy in hospitalized COVID-19 patients. The study confirmed an acceptable safety profile and reported a low one-month mortality rate of 6.7% and a 90-day mortality rate of 8.0%, which is favorable for this severe patient population.[42][ This successful repurposing provided powerful, real-world clinical evidence validating Itolizumab's core mechanism of controlling systemic hyperinflammation by acting as an upstream immunomodulator.]

Exploratory Indications

[Itolizumab has been explored in other autoimmune diseases with varying degrees of success:]

• Rheumatoid Arthritis (RA): Early Phase I, open-label, dose-finding studies in patients with active RA demonstrated a good safety profile and encouraging signs of efficacy. Objective clinical responses, as measured by the American College of Rheumatology 20% improvement criteria (ACR20), were achieved in over 80% of patients, and these responses tended to be sustained after treatment completion.[7]
• Uncontrolled Asthma: The Phase 1b EQUIP study in patients with uncontrolled moderate-to-severe asthma met its primary objective of safety and tolerability. Pharmacodynamic data confirmed rapid and sustained target engagement, with a significant reduction in cell surface CD6 expression.[46] While Asthma Control Questionnaire (ACQ-6) scores showed numerical improvement, the efficacy signal was less clear, as several patients in the treatment arms experienced asthma exacerbations requiring systemic corticosteroids.[46]

Trial Name/ID	Indication	Phase	Key Design	Primary Endpoint	Key Result	Source(s)
treat-Plaq	Plaque Psoriasis	III	RCT, Placebo-controlled	PASI-75 @ 12 wks	Met	5
EQUATOR (NCT05263999)	aGVHD (1st Line)	III	RCT, Placebo-controlled	CR @ Day 29	Not Met (but long-term endpoints met)	27
UC Ph2	Ulcerative Colitis	II	RCT, Placebo & Active-controlled	Clinical Remission @ 12 wks	Met (comparable to adalimumab)	31
EQUALISE (NCT04128579)	Lupus Nephritis	Ib	Open-label	Safety/Tolerability	Positive signal (↓UPCR)	35
COVID-19 Ph2	COVID-19 ARDS	II	RCT, Controlled	Mortality @ 1 mo	Met (↓mortality)	43
RESURRECT	COVID-19 ARDS	IV	Single-arm	Safety/Mortality @ 1 mo	Favorable safety, low mortality	42
Table 2: Summary of Key Clinical Trials for Itolizumab

Safety, Tolerability, and Clinical Pharmacology

[A comprehensive evaluation of Itolizumab's clinical profile reveals a consistent and generally favorable safety and tolerability record across a diverse range of patient populations and disease states.]

Consolidated Safety Profile

Across numerous clinical trials, from early-phase studies in rheumatoid arthritis to pivotal trials in psoriasis and aGVHD, Itolizumab has been well-tolerated.[4]

• Infusion-Related Reactions (IRRs): The most common treatment-emergent adverse events (TEAEs) are acute IRRs that occur during or shortly after intravenous administration. These reactions are characterized by symptoms such as pyrexia (fever), chills or rigors, headache, nausea, pruritus (itching), and sometimes changes in blood pressure.[42] These events are typically mild to moderate in severity (Grade 1-2), are most frequent during the first infusion, and their incidence and severity tend to decrease with subsequent doses. They are generally manageable with standard measures, including pre-medication with corticosteroids and antihistamines, and by slowing the infusion rate.[20] In a large study of 300 COVID-19 patients, the incidence of severe (≥Grade 3) acute IRRs was low, at 1.3%.[42]
• Infections: A key differentiator in Itolizumab's safety profile is its low association with serious or opportunistic infections. This clinical observation strongly supports the biological hypothesis that its selective immunomodulatory mechanism is less broadly immunosuppressive than agents that cause T-cell depletion or widespread cytokine blockade.[24] Most notably, in the Phase 3 EQUATOR trial for aGVHD, a population highly susceptible to infection, the incidence of infection-related serious adverse events (28.2% vs. 37.7%) and sepsis (5.1% vs. 18.2%) was numerically lower in the Itolizumab arm compared to the placebo arm (which received corticosteroids alone).[28]
• Lymphopenia: A transient, dose-dependent decrease in absolute lymphocyte counts (lymphopenia) is a recognized pharmacodynamic effect of Itolizumab.[36] However, this laboratory finding has not been associated with clinical sequelae or an increased risk of infection in clinical trials.[36]

Pharmacokinetics (PK) and Pharmacodynamics (PD)

Comprehensive data on the pharmacokinetics of Itolizumab, including detailed absorption, distribution, metabolism, and excretion (ADME) profiles, are not extensively available in the public domain.[45]

• Pharmacokinetics: Preliminary PK data from the Phase 1b EQUALISE study, which used subcutaneous administration, indicated that drug exposure (as measured by Cmax​ and AUC) increased in a dose-proportional manner.[36] The terminal elimination half-life following intravenous administration has been reported to be approximately 18.5 days, which is consistent with other IgG1 monoclonal antibodies and supports dosing intervals of every two to four weeks.[18]
• Pharmacodynamics: The primary pharmacodynamic marker for Itolizumab is target engagement, which is directly measured by the occupancy of the CD6 receptor on T-cells. Clinical studies have consistently demonstrated that Itolizumab administration leads to a rapid, dose-dependent, and sustained reduction in the expression of CD6 on the surface of circulating T-cells.[32][ This provides clear evidence of biological activity and confirms that the drug is reaching and binding to its intended target in a durable manner.]

Contraindications, Warnings, and Drug Interactions

[Based on prescribing information and clinical trial experience, the following safety considerations are paramount for the use of Itolizumab:]

• Contraindications:
• Patients with a known history of severe hypersensitivity to Itolizumab, any of its excipients, or other murine-derived proteins.[8]
• Patients with active, severe infections.[52]
• Patients with severe immunocompromise.[52]
• Warnings and Precautions:
• Tuberculosis (TB): As with other immunomodulatory biologics, patients must be evaluated for both active and latent TB infection prior to initiating therapy and monitored for signs and symptoms of TB during treatment. This screening typically involves a tuberculin skin test or an interferon-gamma release assay (IGRA) and a chest x-ray.[18]
• Infections: Caution should be exercised when considering Itolizumab for patients with a history of chronic or recurrent infections. It should also be used cautiously in patients with underlying conditions that may predispose them to infection, such as HIV or chronic viral hepatitis (Hepatitis B or C).[20]
• Special Populations: The safety and efficacy of Itolizumab have not been established in pediatric patients under 18 years of age (outside of clinical trials), in pregnant or breastfeeding women, or in patients with significant hepatic or renal impairment. Use in these populations is generally not recommended, and caution with regular monitoring is advised if treatment is deemed necessary.[18]
• Drug Interactions:
• Live Vaccines: Co-administration of live or live-attenuated vaccines with Itolizumab is not recommended. Due to its immunomodulatory effects, Itolizumab may potentiate the replication of vaccine organisms and increase the risk of infection.[48]

Global Regulatory and Commercial Landscape

[The regulatory and commercial journey of Itolizumab is a tale of two distinct paths: one of successful development and approval in India and Cuba, and another of significant challenges and setbacks in the stringent regulatory environments of the United States and Europe.]

Path to Market in India and Cuba

Itolizumab is the product of a collaboration between the Center of Molecular Immunology (CIM) in Havana, Cuba, and the Indian biopharmaceutical company Biocon.[5][ This partnership led to its initial regulatory success.]

• Psoriasis Approval: The Drugs Controller General of India (DCGI) granted marketing authorization for Itolizumab in January 2013 for the treatment of moderate-to-severe chronic plaque psoriasis.[5] It is also approved for this indication in Cuba.[11]
• COVID-19 Emergency Use: In a rapid response to the global pandemic, the DCGI granted a restricted emergency use authorization for Itolizumab in July 2020 to treat cytokine release syndrome (CRS) in patients with moderate-to-severe ARDS caused by COVID-19, making it one of the first novel biologics to be approved for this complication anywhere in the world.[21]

The U.S. FDA Trajectory: A Case Study in Regulatory Challenges

In 2017, Biocon out-licensed the development and commercialization rights for Itolizumab in the United States, Canada, Australia, and New Zealand to Equillium, a U.S.-based biotechnology company.[10][ Equillium has since spearheaded its development in these territories, focusing on high unmet need autoimmune and inflammatory disorders.]

[The U.S. Food and Drug Administration (FDA) initially showed support for the program by granting special designations intended to expedite the development of promising therapies:]

• Orphan Drug Designation: Granted in February 2019 for the treatment of aGVHD.[55]
• Fast Track Designation: Granted in December 2019 for the treatment of lupus nephritis.[41]

Despite this early encouragement, the program faced a pivotal setback in April 2025. Following a review of the topline data from the Phase 3 EQUATOR trial in first-line aGVHD, the FDA declined to grant Breakthrough Therapy designation and did not support an accelerated approval pathway for the drug.[29] The agency's feedback focused almost exclusively on the trial's failure to meet its Day 29 primary endpoint for complete response, deeming the positive long-term secondary endpoint data insufficient to support an accelerated filing at that time.[29] This decision was a major blow to the aGVHD program in the U.S. and prompted Equillium to accelerate the closure of the EQUATOR study.[29]

European Outlook: The Paediatric Investigation Plan (PIP)

Itolizumab does not currently hold marketing authorization from the European Medicines Agency (EMA). However, the regulatory process in Europe remains active. In May 2023, the EMA's Paediatric Committee (PDCO) formally agreed to a Paediatric Investigation Plan (PIP) for Itolizumab for the treatment of aGVHD.[56] A PIP is a mandatory and binding research and development plan required by the EMA to ensure that necessary data are obtained on the use of a medicine in children. Agreement on a PIP is a prerequisite for submitting a Marketing Authorisation Application (MAA) for any new medicine in the European Union. The agreed plan includes a study in children aged 28 days to less than 12 years and outlines a timeline for completion by August 2029.[56]

[The divergent paths taken by the U.S. and European regulators create significant strategic complexity for the drug's sponsor. The FDA's decision has effectively closed the near-term path to market for aGVHD in the U.S., likely necessitating a new, costly, and redesigned pivotal trial. In contrast, the EMA's procedural engagement through the PIP indicates that the regulatory pathway for aGVHD remains open in Europe. This suggests the EMA may be more receptive to an MAA that is based on the totality of the evidence from the EQUATOR study, including the compelling long-term data. This regulatory divergence may force a bifurcated global strategy, with a potential long-term path for aGVHD in Europe, while the U.S. development focus pivots decisively toward the more promising indications of ulcerative colitis and lupus nephritis.]

Date	Regulatory Body	Action/Milestone	Indication	Implication	Source(s)
Jan 2013	DCGI (India)	Marketing Authorization	Plaque Psoriasis	First commercial launch of the drug.	5
Feb 2019	U.S. FDA	Orphan Drug Designation	Acute Graft-Versus-Host Disease (aGVHD)	Provides incentives to facilitate development for a rare disease.	55
Dec 2019	U.S. FDA	Fast Track Designation	Lupus Nephritis	Designed to expedite the review process for a serious condition.	41
Jul 2020	DCGI (India)	Restricted Emergency Use Authorization	COVID-19 CRS	First biologic approved for COVID-19 CRS based on mortality benefit.	21
May 2023	EMA	Paediatric Investigation Plan (PIP) Agreement	Acute Graft-Versus-Host Disease (aGVHD)	Mandatory step for any future Marketing Authorisation Application in the EU.	56
Apr 2025	U.S. FDA	Rejection of Breakthrough Therapy & Accelerated Approval	Acute Graft-Versus-Host Disease (aGVHD)	Major setback; requires a new pivotal trial for U.S. approval in this indication.	29
Table 3: Global Regulatory Milestones and Status for Itolizumab

Synthesis and Future Outlook

[Itolizumab has established itself as a first-in-class immunomodulator with a distinct mechanism and a compelling safety profile. However, its clinical and regulatory journey has been complex, marked by both clear successes and significant challenges that have reshaped its strategic development path. An integrated analysis reveals a drug whose primary value proposition has evolved from its initial indications to new areas where its unique attributes may be better aligned with clinical needs.]

Integrated Analysis

• Strengths:[ The primary strength of Itolizumab is its novel, selective mechanism of action that modulates T-cell activity without causing broad immunosuppression. This translates directly into its most significant clinical advantage: a highly favorable safety profile characterized by a low risk of serious infections, even in vulnerable patient populations. This safety record has been consistent across all clinical programs. Furthermore, the drug has demonstrated the potential for durable responses, as seen in long-term follow-up in psoriasis and the significant improvement in long-term outcomes in aGVHD. Finally, it has shown strong proof-of-concept in high-value indications with significant unmet need, particularly ulcerative colitis and lupus nephritis.]
• Weaknesses:[ The most significant weakness is the failure of the pivotal EQUATOR trial to meet its short-term primary endpoint in aGVHD, which led to a major regulatory setback with the U.S. FDA and has cast doubt on its utility in acute, hyperinflammatory conditions requiring rapid, potent immunosuppression. In the psoriasis market, it is perceived as having lower peak efficacy compared to the latest generation of biologics, limiting its commercial potential as a first-line agent. The lack of extensive, publicly available pharmacokinetic data is also a minor gap in its overall profile.]
• Opportunities:[ The most significant opportunities for Itolizumab now lie in chronic autoimmune diseases where long-term safety and durable disease control are paramount. The positive Phase 2 data in ulcerative colitis, showing parity with a standard-of-care agent, presents a clear path to a pivotal program in a large market. Similarly, the strong efficacy signals in the high-unmet-need area of lupus nephritis, supported by an FDA Fast Track designation, represent another high-priority development path. There may also be a long-term opportunity to secure approval for aGVHD in Europe, where regulators may take a more holistic view of the long-term survival and durability data.]
• Threats:[ The primary threat is the high cost, long timeline, and uncertain outcome of conducting a new pivotal trial for aGVHD in the U.S. with a redesigned endpoint. In all of its target indications, Itolizumab faces intense competition from a host of established and emerging biologics and small molecules, requiring it to demonstrate a clearly differentiated value proposition to succeed commercially.]

Forward-Looking Perspective

[Despite the significant setback in its lead U.S. indication, the future for Itolizumab is not foreclosed; rather, its strategic focus has been clarified and refined. The clinical and regulatory feedback has effectively shifted its value proposition away from being a therapy for acute, severe inflammation, where rapid and potent effects are the primary measures of success. Instead, its core strengths—excellent long-term safety, tolerability, and the ability to induce durable immunomodulation—are best suited for the chronic management of autoimmune diseases.]

[The most promising and commercially viable paths forward are now clearly in ulcerative colitis and lupus nephritis. In these conditions, where patients often require lifelong therapy, a treatment that offers efficacy comparable to existing standards but with a superior safety profile, particularly a lower risk of infection, would be a highly valuable and differentiated addition to the therapeutic armamentarium. Success in Phase 3 trials for these indications could establish Itolizumab as a best-in-class therapy for specific patient segments.]

[The story of Itolizumab serves as a critical case study in modern drug development. It highlights the immense challenge of aligning a novel biological mechanism with established clinical trial designs and rigid regulatory paradigms. While the failure to meet a traditional short-term endpoint in aGVHD was a major hurdle, the totality of the data continues to support the underlying science. The future success of Itolizumab will depend on the ability of its sponsors to strategically navigate this complex landscape, focusing on the chronic diseases where its unique profile of safety and durability can provide the most meaningful benefit to patients.]

Works cited

1. Itolizumab (Anti-Human CD6 Recombinant Antibody) | Anti-CD6 MAb | MedChemExpress, accessed September 19, 2025, https://www.medchemexpress.com/itolizumab.html
2. Itolizumab (Anti-CD6) CD markers antibody | Read Reviews & Product Use Citations, accessed September 19, 2025, https://www.selleckchem.com/products/itolizumab-anti-cd6.html
3. Itolizumab Biosimilar – Anti-CD6 mAb – Research Grade - ProteoGenix, accessed September 19, 2025, https://us.proteogenix.science/product/itolizumab-biosimilar-anti-cd6-mab-research-grade/
4. Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/276072024_Itolizumab_-_A_humanized_anti-CD6_monoclonal_antibody_with_a_better_side_effects_profile_for_the_treatment_of_psoriasis
5. Itolizumab - Wikipedia, accessed September 19, 2025, https://en.wikipedia.org/wiki/Itolizumab
6. Itolizumab - Biocon/Equillium - AdisInsight - Springer, accessed September 19, 2025, https://adisinsight.springer.com/drugs/800026105
7. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis - PubMed Central, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3862386/
8. Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India, accessed September 19, 2025, https://www.dovepress.com/spotlight-on-itolizumab-in-the-treatment-of-psoriasis-current-perspect-peer-reviewed-fulltext-article-PTT
9. Itolizumab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 19, 2025, https://synapse.patsnap.com/drug/2f8104a08552434bb77560ff860a368b
10. Itolizumab - world's first novel anti-CD6 monoclonal antibody in India - Biocon, accessed September 19, 2025, https://www.biocon.com/businesses/novel-biologics/itolizumab/
11. Itolizumab in Psoriasis - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5527725/
12. Itolizumab Overview - Creative Biolabs, accessed September 19, 2025, https://www.creativebiolabs.net/itolizumab-overview.htm
13. a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. | DrugBank Online, accessed September 19, 2025, https://go.drugbank.com/articles/A226090
14. Itolizumab - Equillium, accessed September 19, 2025, https://www.equilliumbio.com/technology/
15. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications - Biocon, accessed September 19, 2025, https://www.biocon.com/docs/itolizumab-an-anti-cd6-monoclonal-antibody-as-a-potential-treatment-for-covid-19-complications.pdf
16. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications - A Blog by Biocon, accessed September 19, 2025, https://bioconblog.com/wp-content/uploads/2020/08/itolizumab-an-anti-cd6-monoclonal-antibody-as-a-potential-treatment-for-covid-19-complications.pdf
17. Full article: Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications - Taylor & Francis Online, accessed September 19, 2025, https://www.tandfonline.com/doi/full/10.1080/14712598.2020.1798399
18. Itolizumab for Injection (r-DNA origin) - Biocon, accessed September 19, 2025, https://www.biocon.com/docs/ALUZUMAB-L-PI.pdf
19. Itolizumab Humanized Recombinant Monoclonal Antibody (MA5-41919), accessed September 19, 2025, https://www.thermofisher.com/antibody/product/Itolizumab-Humanized-Antibody-Recombinant-Monoclonal/MA5-41919
20. Untitled - Biocon, accessed September 19, 2025, https://www.biocon.com/docs/PI-AlzumabL.pdf
21. Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour? - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7551520/
22. Head-to-Head Study Shows Ixekizumab Outperforms Adalimumab in Psoriatic Arthritis, accessed September 19, 2025, https://www.centerforbiosimilars.com/view/headtohead-study-shows-ixekizumab-outperforms-adalimumab-in-psoriatic-arthritis
23. SKYRIZI® (risankizumab‐rzaa) vs Other Biologics, accessed September 19, 2025, https://www.skyrizi.com/psoriasis/psoriasis-treatment/skyrizi-vs-other-biologics
24. Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis - PMC - PubMed Central, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4407739/
25. Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5624235/
26. Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis | Case Reports in Dermatology | Karger Publishers, accessed September 19, 2025, https://karger.com/cde/article/9/2/141/55809/Itolizumab-A-New-Biologic-for-Management-of
27. Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease, accessed September 19, 2025, https://www.equilliumbio.com/investors/press-releases/news-details/2025/Equillium-Announces-Results-of-the-Phase-3-EQUATOR-Study-of-Itolizumab-in-First-Line-Treatment-of-Patients-with-Acute-Graft-Versus-Host-Disease/default.aspx
28. Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD - Cure Today, accessed September 19, 2025, https://www.curetoday.com/view/itolizumab-shows-long-term-treatment-benefits-in-acute-gvhd
29. FDA Rejects Breakthrough Designation, Approval for Itolizumab in ..., accessed September 19, 2025, https://www.cancernetwork.com/view/fda-rejects-breakthrough-designation-approval-for-itolizumab-in-acute-gvhd
30. Itolizumab Shows Positive Phase III Results in First-Line Treatment of Acute GVHD - Xtalks, accessed September 19, 2025, https://xtalks.com/itolizumab-shows-positive-phase-iii-results-in-first-line-treatment-of-acute-gvhd-4174/
31. Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis, accessed September 19, 2025, https://www.equilliumbio.com/investors/press-releases/news-details/2025/Equillium-Announces-Positive-Data-from-Phase-2-Study-Evaluating-Itolizumab-in-Patients-with-Moderate-to-Severe-Ulcerative-Colitis/default.aspx
32. Biocon Limited initiates clinical study of Itolizumab for Ulcerative Colitis in India, accessed September 19, 2025, https://www.biocon.com/biocon-limited-initiates-clinical-study-of-itolizumab-for-ulcerative-colitis-in-india/
33. Equillium's Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis, accessed September 19, 2025, https://www.equilliumbio.com/investors/press-releases/news-details/2022/Equilliums-Partner-Biocon-Initiates-Phase-2-Study-of-Itolizumab-in-Ulcerative-Colitis/default.aspx
34. Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - BioSpace, accessed September 19, 2025, https://www.biospace.com/press-releases/equillium-announces-positive-data-from-phase-2-study-evaluating-itolizumab-in-patients-with-moderate-to-severe-ulcerative-colitis
35. NCT04128579 | Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | ClinicalTrials.gov, accessed September 19, 2025, https://www.clinicaltrials.gov/study/NCT04128579
36. Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study - ACR Meeting Abstracts, accessed September 19, 2025, https://acrabstracts.org/abstract/itolizumab-a-novel-anti-cd6-therapy-in-systemic-lupus-erythematosus-patients-interim-safety-results-from-the-phase-1b-equalise-dose-escalation-study/
37. Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | ClinicalTrials.gov, accessed September 19, 2025, https://clinicaltrials.gov/study/NCT04128579?cond=lupus&viewType=Table&rank=10
38. Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis, accessed September 19, 2025, https://www.equilliumbio.com/investors/press-releases/news-details/2022/Equillium-Announces-Positive-Interim-Results-from-the-EQUALISE-Study-in-Subjects-with-Lupus-Nephritis/default.aspx
39. Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis, accessed September 19, 2025, https://www.equilliumbio.com/investors/press-releases/news-details/2024/Equillium-Announces-Positive-Topline-Data-from-the-Type-B-Portion-of-the-Phase-1b-EQUALISE-Study-of-Itolizumab-in-Lupus-Nephritis/default.aspx
40. Drug Update: Itolizumab for Treatment of Lupus Nephritis Improves Kidney Biomarker Levels, accessed September 19, 2025, https://www.lupus.org/news/drug-update-itolizumab-for-treatment-of-lupus-nephritis-improves-kidney-biomarker-levels
41. Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis, accessed September 19, 2025, https://www.equilliumbio.com/investors/press-releases/news-details/2019/Equillium-Granted-U-S--FDA-Fast-Track-Designation-for-Itolizumab-for-the-Treatment-of-Lupus-Nephritis-12-09-2019/default.aspx
42. Itolizumab Publications - Biocon, accessed September 19, 2025, https://www.biocon.com/about-us/scientific-publications/itolizumab-publications/
43. Biocon's Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients, accessed September 19, 2025, https://www.biocon.com/biocons-breakthrough-drug-itolizumab-receives-dcgi-nod-for-emergency-use-in-moderate-to-severe-covid-19-patients/
44. Biocon Presented Insights into Clinical Study That Enabled DCGI Approval of Itolizumab for COVID-19, accessed September 19, 2025, https://www.biocon.com/biocon-presented-insights-into-clinical-study-that-enabled-dcgi-approval-of-itolizumab-for-covid19/
45. The anti‐CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6‐month, open‐label Phase I clinical trial - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5758380/
46. Equillium Announces Data from Phase 1b EQUIP Study ... - Equillium, accessed September 19, 2025, https://www.equilliumbio.com/investors/press-releases/news-details/2022/Equillium-Announces-Data-from-Phase-1b-EQUIP-Study-in-Patients-with-Uncontrolled-Asthma/default.aspx
47. Equillium Press Releases - Biocon, accessed September 19, 2025, https://www.biocon.com/businesses/novel-biologics/itolizumab/equillium-press-releases/
48. Itolizumab: Uses, Side Effects and Medicines | Apollo Pharmacy, accessed September 19, 2025, https://www.apollopharmacy.in/salt/Itolizumab
49. Adverse drug reactions of itolizumab in COVID-19 patient: A case report - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9846913/
50. Severe recalcitrant psoriasis treated with itolizumab, a novel anti-CD6 monoclonal antibody, accessed September 19, 2025, https://ijdvl.com/severe-recalcitrant-psoriasis-treated-with-itolizumab-a-novel-anti-cd6-monoclonal-antibody/
51. Itolizumab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 19, 2025, https://go.drugbank.com/drugs/DB16207
52. Itolizumab - Uses, Dosage, Side Effects, Price, Composition | Practo, accessed September 19, 2025, https://www.practo.com/medicine-info/itolizumab-2093-api
53. Itolizumab: Uses, Dosage, Side-Effects and Mechanism of Action - MrMed, accessed September 19, 2025, https://www.mrmed.in/molecule/itolizumab
54. Itolizumab | Uses, Side Effects & Medicines - Truemeds, accessed September 19, 2025, https://www.truemeds.in/drug-salts/itolizumab-315
55. Search Orphan Drug Designations and Approvals - FDA, accessed September 19, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=646718
56. European Medicines Agency decision P/0178/2023 of 15 May 2023 ..., accessed September 19, 2025, https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2023-ema-decision-15-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-itolizumab-emea-003208-pip02-22_en.pdf